Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

SAN DIEGO, April 8, 2008 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it initiated screening in a Phase 2b clinical trial of APD125 in patients with primary insomnia. APD125 is an oral drug candidate discovered by Arena with the potential to reduce insomnia symptoms and improve sleep maintenance and quality.

The Phase 2b trial of APD125 is a double-blind, randomized, placebo- controlled subjective study evaluating the efficacy and tolerability of APD125 in patients with primary insomnia characterized by difficulty maintaining sleep. The trial, which is expected to enroll a total of approximately 675 male and female patients in about 70 clinical sites in the United States, will evaluate two doses (20 mg and 40 mg) and placebo over 14 nights of treatment. The trial will evaluate standard subjective measurements of sleep, including change from baseline in subjective number of awakenings after sleep onset (sNAASO), which is the primary endpoint.

"We are very encouraged by the emerging profile of APD125. We believe APD125 has the potential to significantly improve sleep maintenance and quality for patients with insomnia without the potential for dependence or impairing psychomotor function," said Jack Lief, Arena's President and Chief Executive Officer. "Results from this trial are expected around year end, and we believe they will increase our understanding of APD125 while supporting ongoing partnership efforts."

In a Phase 2a trial, when compared to placebo, patients treated with APD125 achieved statistically significant improvements in objective measurements of sleep maintenance, or the ability to maintain sleep during the night after falling asleep, and sleep architecture. T
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, ... products, announced it received the initial funding to begin ... relief product, for planned distribution to 1,000 medical and ... Washington State , and ... Advanced headache relief gel formulation completed, PuraMed BioScience has ...
(Date:12/24/2014)... 2014 LifeScienceIndustryResearch.com adds ... Syringe Industry of 178 pages providing 10 ... library. The 2014 Market Research ... a professional and deep research report on ... the report introduces Disposable Syringe basic information ...
(Date:12/24/2014)... 23, 2014  The American Diabetes Association is ... for people with diabetes and that all people ... of statins, in keeping with recent changes to ... American College of Cardiology (ACC) and American Heart ... most recent changes to the Association,s annual revised ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... Card, in partnership with The Denver Metro Chamber, announced ... "Preferred Pharmacy" for the program. As part of the ... Drug Card. Coloradans can simply walk into any Walgreens ... through the Colorado Drug Card. Walgreens will also have ...
... a world leading provider of scientific, technical and medical ... today honor eight early career researchers in a range ... Young Researcher Award ceremony. More than 80 university ... attend the award ceremony at the Royal Society in ...
Cached Medicine Technology:Elsevier and the Fulbright Commission Honor UK Research Talent With the UK Scopus Young Researcher Award 2Elsevier and the Fulbright Commission Honor UK Research Talent With the UK Scopus Young Researcher Award 3Elsevier and the Fulbright Commission Honor UK Research Talent With the UK Scopus Young Researcher Award 4
(Date:12/26/2014)... It is said that nothing makes a ... the famous wedding dress supplier, shows its new selection ... gown promotion. , UWDress.com’s navy cocktail gowns are the ... in high fashion styles. Simple dresses in bright neon colors ... they are specially designed for those who want to shine ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Plugin and template ... TransPack Volume 5 Plugin for Final Cut Pro X. , ... hard light tool to pull off an industry professional look” ... get their hands on TransPack Volume 5, a new level ... is a set of over 50 Final Cut Pro X ...
(Date:12/26/2014)... (DaWei Induction Heating Co.) is a comprehensive high-tech business ... of a series of induction heating equipment. Today, the ... induction brazing equipments . , According to a ... refers to the joining of two or more components ... says that there are fundamental differences in the two ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... December 26, 2014 “Every three months the ... changes. A-line sweetheart evening dress will be one of the ... manager of Yunx.co.uk says. Today, the company releases 26 A-line ... up to 80% off. , “We are trying our ... style with our latest designs. Along with affordable prices, we ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2
... The March for Babies 2008 Official Shoes are Now On ... of,Dimes has teamed up with Famous Footwear(TM) and Dr. Scholl,s(R) ... For the third consecutive year, Famous Footwear and Dr. Scholl,s ... walking shoe styles.,Dr. Scholl,s specially designed one men,s and two ...
... Dialysis Corporation,of America (Nasdaq: DCAI ) announced today ... year financial results on March 13, 2008, after the,close ... conference calls,in conjunction with its quarterly earnings releases, beginning ... following morning, March 14,2008 at 10:00 AM EDT., ...
... JERSEY, FEBRUARY 29 -- Otsuka Pharmaceutical Co., Ltd. and ... U.S. Food and Drug Administration (FDA) approved the supplemental ... treatment of manic and mixed episodes associated with Bipolar ... patients (10 to 17 years old). ABILIFY has ...
... study in the Mojave Desert, Calif., has found that soils ... a type of salt, close to the surface. Vulnerable to ... disrupted, this vast source of nitrate could contaminate surface and ... appear in the March issue of Geology . , ...
... of Hematology announce a new partnership to publish the ... available (back to 1997) on Springers online information platform ... and was previously published by Carden Jennings. , Since ... official journal of the Japanese Society of Hematology (JSH), ...
... ATLANTA, Feb. 29 Children,s Healthcare of Atlanta, ... today a,landmark investment in the future of pediatric ... $430 million of the Children,s,endowment toward pediatric research., ... will be,invested in pediatric research," said James E. ...
Cached Medicine News:Health News:Famous Footwear, Dr. Scholl's Step Up to Support March for Babies 2008 2Health News:Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date 2Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 2Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 3Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 4Health News:Large source of nitrate, a potential water contaminant, found in near-surface desert soils 2Health News:Large source of nitrate, a potential water contaminant, found in near-surface desert soils 3Health News:Springer to publish International Journal of Hematology 2Health News:Children's Healthcare of Atlanta Announces Major Investment in Pediatric Research as Part of 10-Year Vision 2Health News:Children's Healthcare of Atlanta Announces Major Investment in Pediatric Research as Part of 10-Year Vision 3
Jewelers forceps. Insulated....
Semkin forceps with stops. Insulated....
Gerald bayonet forceps. Insulated....
Cushing forceps. Insulated....
Medicine Products: